IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Clinical trial NCT06647862 · RECRUITING

Trial details

NCT number: NCT06647862
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Myelomonocytic Leukemia

Start date: 2024-11-11
Primary completion: 2026-04-24
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.